It was early one morning in 1996 when Andrew Hopkins, then a PhD biophysics student at Oxford University, had a brainwave as he walked home from a late-night lab meeting.
He was trying to find molecules to fight HIV and to better understand drug resistance.
I remember this idea struck me that there must be a better way to do drug discovery other than the complex and expensive way everyone was following, he says. Why couldnt we design an automated approach to drug design that would use all the information in parallel so that even a humble PhD student could create a medicine? That idea really stuck with me. I remember almost the exact moment to this day. And that was the genesis of the idea that eventually became Exscientia.
It was to prove a lucrative brainwave. Hopkins set up the company in 2012 as a spinout from the University of Dundee, where he was by then working as a professor. It uses artificial intelligence (AI) systems, which are being trained to mimic human creativity, to develop new medicines. This involves the use of automated computer algorithms to sift through large datasets to design novel compounds that can treat diseases, and to help select the right patients for each treatment.
Age 50
Family Married with a 10-year-old daughter. He met his wife, Iva Hopkins Navratilova, at Pfizer. Her business, Kinetic Discovery, merged with his to create the experimental biology labs at Exscientia.
Education Dwr-y-Felin comprehensive and Neath College in south Wales; degree in chemistry at Manchester; doctorate in molecular biophysics at Oxford.
Pay 415,000
Last holiday Czech Republic to visit his wifes family at Easter.
Best advice he has been given My dad worked in a factory. He said to me: Get a good education and get a job you enjoy doing. Its worth an extra six grand a year. And I definitely got a job I enjoy doing.
Biggest career mistake Its too early to tell. He quotes Miles Davis: Its not the note you play thats the wrong note its the note you play afterwards that makes it right or wrong.
Words he overuses Fundamentally; the heart of the matter.
How he relaxes Reading and dog walking. I am a bibliophile. I immerse myself in books to relax.
This approach drastically cuts the time of drug development. Hopkins says that for Exscientias pipeline it has typically taken 12 to 15 months from starting a project to identifying a drug candidate, compared with four and a half years in the traditional pharmaceutical industry.
The average cost of developing a medicine is $2bn, according to Deloittes latest pharma report, and many drugs fail the failure rate is 90% for medicines that are in early clinical studies (where they are tested on humans).
Typically, pharma companies make 2,500 compounds to test them against a specific disease, while AI enables Oxford-based Exscientia to whittle down that number to about 250, Hopkins says. Its a much more methodical approach.
Last autumn, the Welsh scientist became one of Britains richest entrepreneurs, with a paper fortune of 400m after the company achieved a $2.9bn stock market debut on Nasdaq in New York, making it one of Britains biggest biotech firms. Hopkinss stake of nearly 16% is now worth 170m, as the share price has lost 60% of its value in a bloodbath for Wall Street stocks.
Exscientia was part of a transatlantic trend that is defying government attempts to build a biotech powerhouse in the UK. Abcam, a pioneering Cambridge antibody company, recently announced it was moving its stock market listing from the UK to the US. We are a British company; we choose to be in Oxford because we can attract global talent, Hopkins says. But to be seen as a global company, we listed on what is the global technology index, which is Nasdaq. What we have now is an incredibly international shareholder base from across the world.
The business came up with the first AI-designed drug to enter clinical trials a treatment for obsessive-compulsive disorder in partnership with Japans Sumitomo, although Sumitomo later decided not to proceed with it. The Japanese firm is currently studying another drug developed by Exscientia, for the treatment of Alzheimers disease psychosis, in early human trials.
Hopkins, now 50, fell in love with science thanks to an inspirational chemistry teacher. He has worked as a scientist since the age of 16, when he did a stint in industrial chemistry at the Port Talbot steelworks in south Wales, which he says taught him about the benefits of automation in boosting productivity.
He spent nearly a decade at the US drug giant Pfizer, where he was on a data warehouse project that led to some of the first machine-learning applications in the pharmaceutical industry, with the findings published in Nature in 2006.
During the subsequent five years at Dundee University, he further researched applying data mining and machine learning to drug discovery. He says being a professor is actually one of the best jobs in the world and gave him the freedom to research AI methods at length. He maintains his links with the university, where he is honorary chair of medicinal informatics at the School of Life Sciences.
Exscientia (which means from knowledge in Latin) soon moved to the Schrdinger Building at the Oxford science park, and now employs 450 people worldwide, from Vienna to Boston, Miami and Osaka, equally split between AI engineering, chemistry and biology.
It is building a new robotics laboratory at Milton Park near Oxford, focused on the automation of chemistry and biology to accelerate drug development and its declared goal is drugs designed by AI, made by robot. Other pharma companies have also introduced some automation into their processes, but generally lab technology is similar to how it was when he was a student in the 1990s, Hopkins says.
The firm is involved in 30 projects, some in partnership with big pharmaceutical companies including Frances Sanofi and the US firm Bristol Myers Squibb (BMS). It is also working with Oxford University on developing medicines that target neuroinflammation for the treatment of Alzheimers disease. Among the firms solo projects, a cancer drug for solid tumours is about to go into early clinical trials.
Exscientia is also working on a broader coronavirus pill to rival Paxlovid, the Covid-19 treatment made by Hopkinss former employer Pfizer. This work is funded by a $1.5m grant from the Bill and Melinda Gates Foundation, which took a stake in Exscientia. The companys other investors include BMS, Celgene (now a BMS subsidiary) and Germanys Evotec, as well as Japans Softbank, the US fund manager BlackRock and the life science investor Novo Holdings.
Hopkins says the team has identified a set of molecules that could work as a broader treatment for Covid-19, new mutations and other coronaviruses, and that there will be more news later this year. The firm is aiming for a low-cost pill that could be distributed globally and given quickly to people who fall ill to prevent serious illness and hospitalisation. Covid-19 infections are rising again in 110 countries and the World Health Organizations director general, Tedros Adhanom Ghebreyesus, has warned that the pandemic is far from over.
Firms across the pharmaceutical industry have started using AI in recent years. AstraZeneca is investing heavily in it for its entire research and development infrastructure, and GSK has built an AI team of 120 engineers, with plans to reach 160 next year, making it the largest such in-house team in the industry.
AI systems require a lot of computing power and enormous datasets. Their use should boost the number of new drugs being approved every year typically 40 to 50 in the US to many more. Hopkins confidently predicts: This is the way all drugs will be designed in the future. In the next decade, this technology will become ubiquitous.
The sub-heading of this article was amended on 31 July 2022. An earlier version referred to the employment of AI to to drastically reduce the speed of drug development when cut the time of drug development was meant.
See the original post here:
Andrew Hopkins of Exscientia: the man using AI to cure disease - The Guardian
- Chinese national arrested and charged with stealing AI trade secrets from Google - NPR - March 8th, 2024 [March 8th, 2024]
- President Biden Calls for Ban on AI Voice Impersonations During State of the Union - Variety - March 8th, 2024 [March 8th, 2024]
- Revolutionize Your Business with AWS Generative AI Competency Partners | Amazon Web Services - AWS Blog - March 8th, 2024 [March 8th, 2024]
- Broadcom Expects AI Demand to Help Offset Weakness Elsewhere - Yahoo Finance - March 8th, 2024 [March 8th, 2024]
- Micron Hits Record High With Analysts Calling It an 'Under-Appreciated AI Beneficiary' - Investopedia - March 8th, 2024 [March 8th, 2024]
- The Adams administration quietly hired its first AI czar. Who is he? - City & State New York - March 8th, 2024 [March 8th, 2024]
- AI likely to increase energy use and accelerate climate misinformation report - The Guardian - March 8th, 2024 [March 8th, 2024]
- This Artificial Intelligence (AI) Stock Could Double, and It Is Way Cheaper Than Nvidia - Yahoo Finance - March 8th, 2024 [March 8th, 2024]
- Fake images made to show Trump with Black supporters highlight concerns around AI and elections - The Associated Press - March 8th, 2024 [March 8th, 2024]
- Artificial intelligence and illusions of understanding in scientific research - Nature.com - March 8th, 2024 [March 8th, 2024]
- Analysis | House AI task force leaders take long view on regulating the tools - The Washington Post - March 8th, 2024 [March 8th, 2024]
- Don't Give Your Business Data to AI Companies - Dark Reading - March 8th, 2024 [March 8th, 2024]
- NIST, the lab at the center of Bidens AI safety push, is decaying - The Washington Post - March 8th, 2024 [March 8th, 2024]
- Essay | AI is Coming! Tips for Staying Calm and Carrying On - The Wall Street Journal - March 8th, 2024 [March 8th, 2024]
- AI can be easily used to make fake election photos - report - BBC.com - March 8th, 2024 [March 8th, 2024]
- 5 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - Yahoo Finance - March 8th, 2024 [March 8th, 2024]
- AI could be an extraordinary force for good. So why do our politicians still not have a plan? - The Guardian - March 8th, 2024 [March 8th, 2024]
- Mapping Disease Trajectories from Birth to Death with AI - Neuroscience News - March 8th, 2024 [March 8th, 2024]
- India plans 10,000-GPU sovereign AI supercomputer - The Register - March 8th, 2024 [March 8th, 2024]
- SAP enhances Datasphere and SAC for AI-driven transformation - CIO - March 8th, 2024 [March 8th, 2024]
- Jim Cramer names companies and sectors poised to rally on the AI wave - CNBC - March 8th, 2024 [March 8th, 2024]
- The job applicants shut out by AI: The interviewer sounded like Siri - The Guardian - March 8th, 2024 [March 8th, 2024]
- Microsoft confirms Surface and Windows AI event for March 21st - The Verge - March 8th, 2024 [March 8th, 2024]
- Adobes new Express app brings Firefly AI tools to iOS and Android - The Verge - March 8th, 2024 [March 8th, 2024]
- A Google AI Watched 30,000 Hours of Video GamesNow It Makes Its Own - Singularity Hub - March 8th, 2024 [March 8th, 2024]
- Palantir CEO Karp on TITAN, AI Warfare Technology - Bloomberg - March 8th, 2024 [March 8th, 2024]
- Elliptic Curve Murmurations Found With AI Take Flight - Quanta Magazine - March 8th, 2024 [March 8th, 2024]
- 5 AI Stocks to Buy in March 2024, According to Analysts - TipRanks.com - TipRanks - March 8th, 2024 [March 8th, 2024]
- Wix's new AI chatbot builds websites in seconds based on prompts - The Verge - March 8th, 2024 [March 8th, 2024]
- Amid record high energy demand, America is running out of electricity - The Washington Post - March 8th, 2024 [March 8th, 2024]
- AI Crypto Tokens in 5 Minutes: What to Know and Where to Start - Inc. - February 26th, 2024 [February 26th, 2024]
- 'The Worlds I See' by AI visionary Fei-Fei Li '99 selected as Princeton Pre-read - Princeton University - February 26th, 2024 [February 26th, 2024]
- AI is having a 1995 moment, analyst says - Business Insider - February 26th, 2024 [February 26th, 2024]
- Vatican research group's book outlines AI's 'brave new world' - National Catholic Reporter - February 26th, 2024 [February 26th, 2024]
- Honor's Magic 6 Pro launches internationally with AI-powered eye tracking on the way - The Verge - February 26th, 2024 [February 26th, 2024]
- Google explains Gemini's embarrassing AI pictures of diverse Nazis - The Verge - February 26th, 2024 [February 26th, 2024]
- Google cut a deal with Reddit for AI training data - The Verge - February 26th, 2024 [February 26th, 2024]
- What's the point of Elon Musk's AI company? - The Verge - February 26th, 2024 [February 26th, 2024]
- AI agents like Rabbit aim to book your vacation and order your Uber - NPR - February 26th, 2024 [February 26th, 2024]
- Announcing Microsofts open automation framework to red team generative AI Systems - Microsoft - February 26th, 2024 [February 26th, 2024]
- After Nvidia's latest blowout, here are 20 AI stocks expected to rise as much as 44% - Yahoo Finance - February 26th, 2024 [February 26th, 2024]
- 1 Exceptional AI Chip Stock Investors Need to Know About in 2024 - The Motley Fool - February 26th, 2024 [February 26th, 2024]
- Nvidia briefly hits $2 trillion valuation as AI frenzy grips Wall Street - Reuters - February 26th, 2024 [February 26th, 2024]
- AI Chatbots Can Guess Your Personal Information From What You ... - WIRED - October 18th, 2023 [October 18th, 2023]
- Harvard IT Launches Pilot of AI Sandbox to Enable Walled-Off Use ... - Harvard Crimson - October 18th, 2023 [October 18th, 2023]
- Advancing policing through AI: Insights from the global law ... - Police News - October 18th, 2023 [October 18th, 2023]
- Hochul announces new SUNY, IBM investments in AI - Olean Times Herald - October 18th, 2023 [October 18th, 2023]
- Nvidia's banking on TensorRT to expand its generative AI dominance - The Verge - October 18th, 2023 [October 18th, 2023]
- AI expands from MRFs to vehicles - Plastics Recycling Update - October 18th, 2023 [October 18th, 2023]
- AI Reads Ancient Scroll Charred by Mount Vesuvius in Tech First - Scientific American - October 18th, 2023 [October 18th, 2023]
- A DEEPer (squared) dive into AI Harvard Gazette - Harvard Gazette - October 18th, 2023 [October 18th, 2023]
- Florida bar weighs whether lawyers using AI need client consent - Reuters - October 18th, 2023 [October 18th, 2023]
- Cognizant and Vianai Systems Announce Strategic Partnership to ... - PR Newswire - October 18th, 2023 [October 18th, 2023]
- How AI could speed up scientific discoveries, from proteins to ... - NPR - October 18th, 2023 [October 18th, 2023]
- AI challenge to deliver better healthcare | Western Australian ... - Government of Western Australia - October 18th, 2023 [October 18th, 2023]
- Henry Kissinger: The Path to AI Arms Control - Foreign Affairs Magazine - October 18th, 2023 [October 18th, 2023]
- Stability AI releases StableStudio in latest push for open-source AI - The Verge - May 18th, 2023 [May 18th, 2023]
- Google CEO Sundar Pichai Predicts That This Profession Will Be ... - The Motley Fool - May 18th, 2023 [May 18th, 2023]
- Frances privacy watchdog eyes protection against data scraping in AI action plan - TechCrunch - May 18th, 2023 [May 18th, 2023]
- Investing in Hippocratic AI - Andreessen Horowitz - May 18th, 2023 [May 18th, 2023]
- As Alphabet flexes its AI prowess, there's a 'new elephant in the room' for Google - MarketWatch - May 18th, 2023 [May 18th, 2023]
- The Boring Future of Generative AI | WIRED - WIRED - May 18th, 2023 [May 18th, 2023]
- OpenAI readies new open-source AI model, The Information reports - Reuters.com - May 18th, 2023 [May 18th, 2023]
- What every CEO should know about generative AI - McKinsey - May 18th, 2023 [May 18th, 2023]
- AI creates images of the 'perfect' man and woman - Sky News - May 18th, 2023 [May 18th, 2023]
- Audit AI search tools now, before they skew research - Nature.com - May 18th, 2023 [May 18th, 2023]
- 3 Reasons C3.ai Stock Could Be Your Golden Ticket to the AI ... - InvestorPlace - May 18th, 2023 [May 18th, 2023]
- Zoom makes a big bet on AI with investment in Anthropic - VentureBeat - May 18th, 2023 [May 18th, 2023]
- AI voice phone scams are on the rise. Here's how to avoid them - USA TODAY - May 18th, 2023 [May 18th, 2023]
- Amazon is building an AI-powered conversational experience for ... - The Verge - May 18th, 2023 [May 18th, 2023]
- AI speculators need to 'differentiate between actual spending and investment' and hype: Strategist - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- AI Can Be Both Accurate and Transparent - HBR.org Daily - May 18th, 2023 [May 18th, 2023]
- You're Probably Underestimating AI Chatbots | WIRED - WIRED - May 18th, 2023 [May 18th, 2023]
- AI presents political peril for 2024 with threat to mislead voters - The Associated Press - May 18th, 2023 [May 18th, 2023]
- We need AI to help us face the challenges of the future - The Guardian - May 18th, 2023 [May 18th, 2023]
- End Of Googles Dominance? Stock Gets Rare Analyst Downgrade Over AI Fears - Forbes - May 18th, 2023 [May 18th, 2023]
- Watch 44 million atoms simulated using AI and a supercomputer - New Scientist - May 18th, 2023 [May 18th, 2023]
- AI Is The New Electricity: Bank Of America Picks 20 Stocks To Cash In On ChatGPT Hype - Forbes - March 2nd, 2023 [March 2nd, 2023]
- Tech Giants Are Barreling Headfirst Into an AI Arms Race - February 20th, 2023 [February 20th, 2023]
- Bing's AI Is Threatening Users. That's No Laughing Matter - TIME - February 20th, 2023 [February 20th, 2023]